84/100B44.290
USD
0.07
(0.15%)
Market Open
Last updated: · Delayed 15 min
Fair value62.64Plus-29%47Price 44.2978
Q4 FY2026 · Earnings report
EPS estimate 0.78Revenue estimate 5.18B
Q4 FY2026 · Earnings report
EPS estimate 0.78Revenue estimate 5.18B
If you had invested in Boston Scientific ago, it would be worth $2,056 today, against $4,096 in SPY and $6,368 in QQQ.
Arincen ScoreWhat is the Arincen Score? The Arincen Score grades a company out of 100 from 30 checks on its own reported figures, five checks in each of six parts.Beta
84/100
Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.
Profitability8
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Cash10
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Valuation10
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Growth10
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Financial strength4
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Shareholders—
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Figures to FY2025; the price as of today.
Boston Scientific key facts
- StyleWhat does a stock's style mean? The style label sorts a stock as growth, value, dividend, blend or speculative, with a 1 to 10 meter showing how strongly it fits.
- Value stock · 8.1/10Growth 4.7 · Value 8.1
- Day range
- 44.130 – 44.560
- 52-week range
- 39.570 – 105.650
- Market capitalizationWhat is market capitalization? Market cap is what the stock market values a whole company at: its share price times the number of its shares outstanding.
- 64.20B USD
- P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 18.69
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 1.20
- EPSWhat is EPS (earnings per share)? EPS (earnings per share) is a company's net income divided by its number of shares: the profit that belongs to each share over a period.
- 2.37
- EPS growth forecast (FY2026)
- +3.7%
- Volume
- 86,827
- BetaWhat is beta in stocks? Beta measures how much a stock tends to move when the whole market moves: 1 moves with it, under 1 is calmer, over 1 swings more.
- 0.59
- ESG scoreWhat is an ESG score? An ESG score rates how a company handles the environment, its people and its governance, out of 100. Higher is better.
- 62.8/100Environment 72 · Social 59 · Governance 57
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Michael F. Mahoney
- Employees
- 59K
- Website
- bostonscientific.com
- IPO date
- 19 May 1992
Boston Scientific earningsWhat is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
Next earnings · Q4 FY2026
EPS estimate
0.78 USD
Revenue estimate
5.18B USD
Last quarter · Q3 FY2026
EPS0.73Beat +0.4%Revenue5.14BBeat +1.0%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q3 FY2027 | 0.77 | — | — | +5.39% | 5.13B | — | — | -0.24% | |
| Q2 FY2027 | 0.80 | — | — | -7.32% | 5.29B | — | — | -2.88% | |
| Q1 FY2027 | 0.75 | — | — | -6.71% | 5.06B | — | — | -2.72% | |
| Q4 FY2026 | 0.78 | — | — | -2.50% | 5.18B | — | — | -2.01% | |
| Q3 FY2026 | 0.73 | 0.73 | +0.41% | -2.67% | 5.09B | 5.14B | +0.99% | +1.44% | |
| Q2 FY2026 | 0.84 | 0.86 | +2.99% | +14.67% | 5.38B | 5.44B | +1.25% | +7.53% | |
| Q1 FY2026 | 0.79 | 0.80 | +1.52% | +6.67% | 5.17B | 5.20B | +0.58% | +11.58% | |
| Q4 FY2025 | 0.78 | 0.80 | +2.43% | +14.29% | 5.28B | 5.29B | +0.12% | +15.90% | |
| Q3 FY2025 | 0.71 | 0.75 | +5.04% | +19.05% | 4.97B | 5.07B | +1.93% | +20.34% | |
| Q2 FY2025 | 0.73 | 0.75 | +3.45% | +20.97% | 4.89B | 5.06B | +3.43% | +22.84% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | 3.35 | — | — | +7.45% | 21.86B | — | — | +5.14% |
| FY2027 | 3.12 | — | — | -1.29% | 20.79B | — | — | -0.84% |
| FY2026 | 3.16 | — | — | +3.70% | 20.97B | — | — | +4.45% |
| FY2025 | 3.04 | 3.05 | +0.45% | +21.51% | 20.07B | 20.08B | +0.02% | +19.88% |
| FY2024 | 2.47 | 2.51 | +1.81% | +22.44% | 16.61B | 16.75B | +0.82% | +17.60% |
| FY2023 | 2.01 | 2.05 | +1.96% | +19.88% | 14.12B | 14.24B | +0.88% | +12.29% |
| FY2022 | 1.73 | 1.71 | -1.41% | +4.91% | 12.68B | 12.68B | -0.02% | +6.68% |
Analysts' estimates for FY2026 over the last 7 days:EPS Revenue How the estimates moved
Boston Scientific analyst forecastWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
12-month price target
54.65 USD
+23.39%
Analysts' 1-year price targets range from 46.00 to 71.00, with an average of 54.65.
Past year
1-year forecast
Strong sellStrong buy
Buy
25 ratings
| Buy | 18 | |
| Hold | 7 | |
| Sell | 0 |
12-month price target
| Highest target | 71.00 |
| Average target | 54.65 |
| Lowest target | 46.00 |
| Current price | 44.29 |
Boston Scientific valuationWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 18.69
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 14.00
- Price to sales (TTM)What is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
- 3.05
- Price to bookWhat is the P/B ratio? The price-to-book ratio compares a company's market value with its book value, the shareholders' equity on its balance sheet.
- 2.50
- EV / EBITDA (TTM)What is EV/EBITDA? EV/EBITDA compares a company's whole value, debt included and cash taken off, with a year of its earnings before interest, tax and depreciation.
- 13.95
Capital structureWhat is enterprise value? Enterprise value is what the whole business costs: the market value of its shares plus its debt minus its cash. It is the price behind EV/EBITDA.
Market capitalization
64.20B USD
+
Total debt
11.95B USD
−
Cash and short-term investments
609.00M USD
=
Enterprise value
75.54B USD
Valuation over time
P/EForward P/EForward P/E · EstimateEstimate
Boston Scientific against its own historyWhat does "against its own history" show? The company's latest margins, return on equity, growth, debt and P/E against its own last 5 years: the low, the median and the high, and whether this year is better or worse than usual.
Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: Edwards Lifesciences, GE HealthCare Technologies, Stryker, DexCom, Abbott Laboratories, and Zimmer Biomet Holdings, the US Medical - Devices companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- P/E (today)Below its median18.718.0117.7
- Gross marginHighest in 5 years69.0%60.8%69.0%Against its peers: 2 of 7Peers' median 60.9%
- Operating marginHighest in 5 years19.8%14.4%19.8%Against its peers: 2 of 7Peers' median 18.8%
- Net marginHighest in 5 years14.4%5.5%14.4%Against its peers: 4 of 7Peers' median 13.8%
- Return on equityHighest in 5 years11.9%4.0%11.9%Against its peers: 5 of 7Peers' median 13.5%
- Free cash flow marginHighest in 5 years18.2%7.4%18.2%Against its peers: 3 of 7Peers' median 17.5%
- Revenue growthAbove its median19.9%6.7%19.9%Against its peers: 1 of 7Peers' median 9.2%
- EPS growthAbove its median55.2%-35.1%140.6%Against its peers: 1 of 7Peers' median -7.5%
- Debt to EBITDALowest in 5 years2.32×2.32×3.75×Against its peers: 4 of 7Peers' median 1.93×
- Current ratioHighest in 5 years1.621.081.62Against its peers: 5 of 7Peers' median 1.89
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
Boston Scientific growth and profitabilityWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.
- 21.07B USD
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- 3.49B USD
- Gross marginWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- 70.37%
- Operating margin
- 21.05%
- Net margin
- 16.56%
Revenue / Net income
Revenue Net income Net margin
Boston Scientific revenue breakdown
By product
FY2025
66.0%Cardiovascular34.0%MedSurg
| Segment | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| Cardiovascular | 13.27B | 66.0% | +23.3% |
| MedSurg | 6.83B | 34.0% | +13.9% |
By region
FY2025
64.1%United States35.9%Non-US
| Region | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| United States | 12.86B | 64.1% | +26.0% |
| Non-US | 7.21B | 35.9% | +10.3% |
How Boston Scientific makes its moneyWhat is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
Cardiovascular13.27B 66.1%
MedSurg6.83B 34.0%
Revenue20.07B 100.0%
Cost of revenue6.22B 31.0%
Gross profit13.85B 69.0%
Research and development2.05B 10.2%
Selling and administration6.89B 34.3%
Other operating expenses943.00M 4.7%
Operating income3.97B 19.8%
Tax493.00M 2.5%
Other expense592.00M 2.9%
Net income2.89B 14.4%
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
Boston Scientific financial health
- Cash and short-term investments
- 609.00M USD
- Total debt
- 11.95B USD
- Net cash
- -11.34B USD
- Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.
- 3.33B USD
- Current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.
- 1.36
- Debt to equityWhat is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
- 0.47
- Piotroski scoreWhat is the Piotroski F-Score? The Piotroski F-Score rates a company's financial strength from 0 to 9: one point for each of nine tests of profit, debt and efficiency it passes.
- 6 / 9
- Altman Z-scoreWhat is the Altman Z-Score? The Altman Z-Score rolls five financial ratios into one number that signals a company's risk of bankruptcy: over 3 is safe, under 1.8 is distress.
- 3.08
Cash, debt and free cash flow
Cash and short-term investments Total debt Free cash flow
Boston Scientific ownershipWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- InstitutionsWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- 90.62%
- Institutional holders
- 1,580 (-191)
- Free floatWhat is free float? Free float is the part of a company's shares that anyone can buy and sell: all its shares minus those held by insiders, founders and owners of over 5%.
- 99.35%
Who owns the shares
Institutions 90.6% Others 9.4%
As of 30 Jun 2026
Shares free to trade
Free float 1.44B shares ·99.3% Closely held 9.45M shares ·0.7%
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Insider trading
| Quarter | Purchases | Sales | Shares acquired | Shares disposed of |
|---|---|---|---|---|
| Q4 2026 | 0 | 0 | 256.11K | 5.74K |
| Q3 2026 | 6 | 0 | 298.98K | 4.84K |
| Q2 2026 | 4 | 0 | 54.44K | 392.54K |
| Q1 2026 | 0 | 2 | 1.03M | 603.90K |
Shares outstanding
Basic shares Diluted shares Change in diluted shares
Source: Financial Modeling Prep
.webp)
Title: Boston Scientific Corp
Sector: Healthcare
Industry: Medical - Devices
Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.